Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatolo
about
Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritisRate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databasesPredictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine.Biologics registers in RA: methodological aspects, current role and future applications.Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008.Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol.Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics RegisterCell therapy for autoimmune diseasesAdalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug.Use of Anti-Tumor Necrosis Factor Therapy: A Retrospective Study of Monotherapy and Adherence to Combination Therapy with Non-Biologic Disease-Modifying Anti-Rheumatic Drugs.Predictors and outcomes of sustained, intermittent or never achieving remission in patients with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register.Challenges in the management of juvenile idiopathic arthritis with etanerceptInfliximab in the treatment of rheumatoid arthritisLong-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug Registers.Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis.Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritisEtanercept: a review of its use in autoimmune inflammatory diseases.Dose modification of anti-TNF in rheumatoid arthritis and estimated economical impact: a review of observational studies.Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis.Biologic monotherapy in the treatment of rheumatoid arthritis.The role of human umbilical cord tissue-derived mesenchymal stromal cells (UCX®) in the treatment of inflammatory arthritis.Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis.A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers.An immunological biomarker to predict MTX response in early RA.Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial.Adult-onset Still's disease with macrophage activation syndrome successfully treated with a combination of methotrexate and etanercept.Twelve years' experience with etanercept in the treatment of rheumatoid arthritis: how it has changed clinical practice.7th EFIS Tatra Immunology Conference. Molecular determinants of T-cell immunity. 24-28 June 2006, High Tatra Mountains, SlovakiaCost–effectiveness of tumor necrosis factor-α antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitisThe British Society for Rheumatology Biologics Register: 6 years onMicroglial pannexin-1 channel activation is a spinal determinant of joint pain
P2860
Q24612869-68D54F62-B6FC-4EAB-BD77-B03A1AE4EB99Q26778600-847A14A9-01CC-4394-AE40-0CEC4625517AQ27692641-509F7412-94DE-4D9A-8CD5-BC734AACD52BQ30234303-2BD4F689-D9F8-4B2E-9A48-0D7667205470Q33646340-ACCC369E-DBB0-4EE0-8AFE-28CB8E3EB5B8Q34395306-92ABF3A6-8717-4C4F-B75B-8ECFD1256062Q34582086-E4A841D8-0C86-41EC-8CF0-854A4CC70B22Q34623922-6EFB1463-FE90-4F33-9A7F-06A8A9274699Q35868954-F7B3552A-F2BD-4A63-A1B8-9438338E336DQ35953319-F8E5E578-B45E-4D06-8322-E5ECC83AE17AQ36171750-1F80A701-EF65-4B90-B44B-53665076C2D0Q36725347-6B109FFF-2317-4B40-A157-7E207B6D7B9EQ36943002-9331FF01-E4EA-4126-B98C-FFE6DE78FDB3Q37195347-2D2FB578-57AD-4E35-BF03-3B1866C2DDE2Q37303219-ACAAAB19-7F2C-4C06-9926-9A424CED928AQ37303230-3135522D-E4DF-4587-BB71-8FA5905EF461Q37338261-216BC8CB-612C-423A-93C0-48596C8CE8D5Q37372556-A23A2EA9-6D26-41C5-A1F2-49B329FF6FD0Q37622219-39A2CDE0-1E75-4FC9-B40E-9CF23B11917AQ38230740-6E4958E0-698D-4899-A246-34F9635534F3Q38306139-ECEAECF5-228E-465F-95CE-E89266419394Q38424589-046DB10E-B727-4D84-A18F-165CA3C35477Q38510023-B1F86BFF-5BCC-4C5F-8761-357552884B8DQ41972955-F7E23F0B-43EF-43B1-9B03-656F33CD3576Q42578542-A24A9A0D-6B9C-4E03-A459-3CD337E21712Q43686385-ACA6FF4D-C1F5-46E6-92A3-A31717A0E9B9Q45830734-92E2DCE3-8CC5-4C1D-A01F-C0AF9F660923Q47384249-E3E44E9A-6598-4800-9662-9BE93E494887Q51450723-CDE606D9-4285-4BC9-B251-81BB098D8BCCQ53650686-540DA38D-1116-4B2E-84F0-411BD505388FQ57105996-0C09844B-CA5C-4CED-A407-C57350834A8DQ57658712-D676F84C-83D9-4DD0-9A7A-2085C26B5F9CQ57751289-A76A4830-B279-4971-AEB6-87C1752A09DBQ58796114-D1E1A615-FB4B-4CA2-A719-681F4BF8A7B2
P2860
Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatolo
description
article
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у 2006
@uk
name
Comparison of the response to ...... British Society for Rheumatolo
@en
Comparison of the response to ...... British Society for Rheumatolo
@nl
type
label
Comparison of the response to ...... British Society for Rheumatolo
@en
Comparison of the response to ...... British Society for Rheumatolo
@nl
prefLabel
Comparison of the response to ...... British Society for Rheumatolo
@en
Comparison of the response to ...... British Society for Rheumatolo
@nl
P2093
P921
P356
P1476
Comparison of the response to ...... heumatology Biologics Register
@en
P2093
Alan J Silman
British Society for Rheumatology Biologics Register
Kath D Watson
Kimme L Hyrich
P304
P356
10.1002/ART.21830
P577
2006-06-01T00:00:00Z